- Conditions
- Chronic Kidney Disease
- Interventions
- Calcium acetate oral solution (COS), Sevelamer carbonate
- Drug
- Lead sponsor
- Fresenius Medical Care North America
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 4
- States / cities
- New Haven, Connecticut • North Haven, Connecticut • New York, New York
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–11
of 11
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Myelodysplastic Syndromes, de Novo, Myelodysplastic Syndromes, Secondary, Myelodysplastic Syndromes, Previously Treated, Treatment-Related Acute Myeloid Leukemia, Therapy-Related Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia With Failed Remission, Lymphoblastic Lymphoma, in Relapse, Lymphoblastic Lymphoma, Refractory, Acute Leukemia of Ambiguous Lineage in Relapse, Acute Leukemia of Ambiguous Lineage
- Interventions
- Venetoclax, Azacitidine, Cytarabine, Methotrexate, Hydrocortisone, Leucovorin, Dexamethasone, Vincristine, Doxorubicin, Dexrazoxane, Calaspargase Pegol, Erwinia asparaginase
- Drug
- Lead sponsor
- Andrew E. Place, MD
- Other
- Eligibility
- 1 Year to 40 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2030
- U.S. locations
- 5
- States / cities
- San Francisco, California • Aurora, Colorado • Atlanta, Georgia + 2 more
- Conditions
- Leukemia, Acute Lymphocytic Leukemia
- Interventions
- Everolimus (RAD001), Cyclophosphamide, Vincristine, Doxorubicin, Dexamethasone, Mesna, Methotrexate, Ara-C (Cytarabine), Methylprednisone, G-CSF
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 10 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2015
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Hypercholesterolemia
- Interventions
- Lapaquistat acetate and rosuvastatin, Rosuvastatin
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 415 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2007
- U.S. locations
- 82
- States / cities
- Birmingham, Alabama • Haleyville, Alabama • Mobile, Alabama + 79 more
- Conditions
- Hypercholesterolemia
- Interventions
- Lapaquistat acetate and stable statin therapy, Stable statin therapy
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 411 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 86
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 83 more
- Conditions
- Hypercholesterolemia
- Interventions
- Lapaquistat acetate and stable statin therapy, Stable statin therapy
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 649 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2007
- U.S. locations
- 13
- States / cities
- Santa Ana, California • Chicago, Illinois • Iowa City, Iowa + 10 more
- Conditions
- Smallpox
- Interventions
- Tecovirimat, sevelamer carbonate oral tablet, sucroferric oxyhydroxide chewable tablet, calcium acetate oral tablet, Lanthanum Carbonate Chewable Tablet
- Drug
- Lead sponsor
- SIGA Technologies
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 44 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Austin, Texas
- Conditions
- Multiple Myeloma
- Interventions
- Melflufen, Pomalidomide, Dexamethasone
- Drug
- Lead sponsor
- Oncopeptides AB
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 495 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 14
- States / cities
- Tucson, Arizona • Fresno, California • Gainesville, Florida + 11 more
- Conditions
- Multiple Myeloma
- Interventions
- Melphalan flufenamide (Melflufen), Dexamethasone, Bortezomib, Daratumumab
- Drug
- Lead sponsor
- Oncopeptides AB
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts • Columbus, Ohio
- Conditions
- Type 2 Diabetes
- Interventions
- Lapaquistat acetate and lipid-lowering therapy, Lipid-lowering therapy
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2007
- U.S. locations
- 18
- States / cities
- Tucson, Arizona • Artesia, California • Jacksonville, Florida + 15 more
- Conditions
- Hyperphosphatemia
- Interventions
- PA21 (Velphoro®), Calcium Acetate (Phoslyra®)
- Drug
- Lead sponsor
- Vifor Fresenius Medical Care Renal Pharma
- Industry
- Eligibility
- Up to 18 Years
- Enrollment
- 85 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 22
- States / cities
- Birmingham, Alabama • Washington D.C., District of Columbia • Miami, Florida + 17 more